ArticleFrontiers in oncology2025
Diagnostic value of ultrasonographic features in breast cancer and its correlation with hormone receptor expression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this research is to investigate the diagnostic value of Ultrasonographic characteristics in breast cancer (BC) and its relation to hormone receptor status. Method: Patients who underwent Breast Neoplasm surgery from January 2020 to December 2022 were included, 68 patients with malignant and 40 patients with benign, based on pathological diagnosis as the reference standard. Each patient volunteered for an elastography imaging examination, and one lesion was evaluated for each patient. Results: Patients had with mean age of 53.57 years (± 6.34), and lesion diameters ranged from 0.53-2.5 cm (1.29 cm ± 0.41). Kappa consistency analysis examined the inter-observer reliability of ultrasound elasticity signs in discriminating malignant from benign neoplasms. The correlation between ultrasonographic features and hormone receptor activity was also determined using Spearman correlation. Possible factors for having malignant BC lesions were tested, and binary logistic regression was utilized to develop the nomogram prediction model. There the malignant and benign groups were statistically significant in terms of ER, PR, Ki-67, HER-2 expression, marginal burrs, calcification foci, lesion diameter, and blood flow signal grading (P-levels < 0.05). The results of elastography indicated substantial concordance with pathological diagnosis (kappa = 0.875; P < 0.01). Statistically significant, positive correlations between breast cancer lesion diameter and Ki-67, burr sign and ER, as well as blood flow signal grading with PR, ER, Ki-67 and HER-2 were also observed. The independent predictors of malignancy in multivariate analysis included calcifications burr sign blood flow grading elasticity score ER and HER-2 (P < 0.05). By analyzing comprehensive clinical characteristics and measuring the total score as 263 points, the nomogram model achieved high validity in predicting the malignancy of breast lesions and could be applied in daily work with a 74.12% predicted probability of malignancy. Discussion: The performance of ultrasound elastography is promising for BC diagnosis, and the association with hormone receptor status is highly significant. Further confirming that the elasticity score has significant clinical value for the diagnosis of malignant breast lesions, in addition to the fact that hormone receptor levels are independent of elasticity score, we can conclude that the elasticity score and hormone receptor levels are two distinct factors for malignant lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.